biotech
biotech Articles
Paratek Pharmaceuticals saw its shares take a solid jump early on Friday after the results from its late-stage trial were released.
Published:
Last Updated:
24/7 Wall St. has picked out the biggest movers and winners on Wednesday, particularly biopharma companies making serious runs in the session.
Published:
Last Updated:
Revance Therapeutics hit a new 52-week low in Tuesday’s session following the release of its late stage trial results.
Published:
Last Updated:
Though Infinity Pharmaceuticals announced that its DYNAMO study met its primary endpoint of overall response rate, the stock was still way down on the day for other reasons.
Published:
Last Updated:
Pfizer made waves early on Tuesday after it announced a new licensing deal with Shire for an investigational biologic.
Published:
Last Updated:
With the market looking decidedly overbought, one good idea is to rotate to stocks that may have lagged but still have solid upside potential.
Published:
Last Updated:
Global Blood Therapeutics has filed with the SEC regarding a secondary offering valued up to $100 million.
Published:
Last Updated:
Eleven Biotherapeutics watched its shares climb early on Monday morning following a key FDA submission.
Published:
Last Updated:
Biotech companies that lost their way last week truly burned shareholders, whether it was due to ASCO, earnings or even unfavorable clinical trial updates.
Published:
Last Updated:
Here are three biotechs that just recently announced successful Phase 2 trial data for drugs with very big addressable markets.
Published:
Last Updated:
Sophiris Bio shares absolutely skyrocketed on Friday following positive results from its Phase 2a proof of concept study of topsalysin in localized prostate cancer.
Published:
Last Updated:
Shares of Global Blood Therapeutics saw a handy gain going into the weekend following positive results from its mid-stage clinical trial.
Published:
Last Updated:
The May 31 short interest data have been compared with the previous report, and short interest moves were mixed in these selected biotech stocks.
Published:
Last Updated:
Selecta Biosciences expects to price more than 4 million shares in the range of $14 to $16 per share for an initial public offering valued up to more than $78 million.
Published:
Last Updated:
Janus Capital has now launched the Obesity ETF, which has a strategy of investing in companies that provide treatment and care for obesity and obesity‐related disease.
Published:
Last Updated: